Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib-thalidomide-low dose dexamethasone induction followed by ixazomib vs placebo maintenance in transplant-ineligible newly diagnosed multiple myeloma
2013-003266-14Phase 2Completed
- Sponsor
- HOVON
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple myeloma (MM) comparing Ixazomib maintenance arm with Placebo maintenance arm (2 arms). Primary endpoints: Maintenance treatment outcome and Toxicity during induction and maintenance. Started Oct 2014; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2013-003266-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003266-14.